Delaware court dismisses Accord claims in Seroquel antitrust litigation

Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.

Get unlimited access to all Global Competition Review content